Chemotherapy for lung cancer (small-cell lung cancer)

Yoichi Nakanishi

Research output: Contribution to journalArticle

Abstract

Untreated small-cell lung cancer (SCLC) is highly sensitive to both chemotherapy and radiotherapy, although its growth is quite rapid. Clinically, SCLC is classified into limited disease (LD) and extensive disease (ED). Although there are no distinct criteria, LD is generally accepted to be a disease which is confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes without malignant effusion, i.e., a disease in which curative radiotherapy is applicable. Nearly 30% of SCLC is LD at the initial diagnosis. LD-SCLC is a potentially curable disease, and standard treatment is chemoradiotherapy, and the concurrent use of chemotherapy and radiotherapy is chosen particularly if the performance status of the patient is 2 or less and the organ function is good. Cisplatin plus etoposide is typically administered together with radiotherapy, since the risk of radiation pneumonia is known to be low when this combination is selected. The median survival time of LD-SCLC is 16 to 24 months and the 5-year survival rate is nearly 15%. Conversely, the median survival time of ED-SCLC is 6-12 months, however, a long-term disease-free survival is rare. Chemotherapy alone is chosen for ED-SCLC. In the Japanese guideline, the combination of cisplatin plus irinotecan is the first choice if tolerable.

Original languageEnglish
Pages (from-to)43-47
Number of pages5
JournalJapanese Journal of Lung Cancer
Volume56
Issue number1
DOIs
Publication statusPublished - Feb 20 2016

Fingerprint

Small Cell Lung Carcinoma
Lung Neoplasms
Drug Therapy
Radiotherapy
irinotecan
Cisplatin
Radiation Pneumonitis
Survival
Mediastinum
Chemoradiotherapy
Etoposide
Disease-Free Survival
Survival Rate
Lymph Nodes
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Chemotherapy for lung cancer (small-cell lung cancer). / Nakanishi, Yoichi.

In: Japanese Journal of Lung Cancer, Vol. 56, No. 1, 20.02.2016, p. 43-47.

Research output: Contribution to journalArticle

Nakanishi, Yoichi. / Chemotherapy for lung cancer (small-cell lung cancer). In: Japanese Journal of Lung Cancer. 2016 ; Vol. 56, No. 1. pp. 43-47.
@article{909209d574c04917bf29504539e0ec7d,
title = "Chemotherapy for lung cancer (small-cell lung cancer)",
abstract = "Untreated small-cell lung cancer (SCLC) is highly sensitive to both chemotherapy and radiotherapy, although its growth is quite rapid. Clinically, SCLC is classified into limited disease (LD) and extensive disease (ED). Although there are no distinct criteria, LD is generally accepted to be a disease which is confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes without malignant effusion, i.e., a disease in which curative radiotherapy is applicable. Nearly 30{\%} of SCLC is LD at the initial diagnosis. LD-SCLC is a potentially curable disease, and standard treatment is chemoradiotherapy, and the concurrent use of chemotherapy and radiotherapy is chosen particularly if the performance status of the patient is 2 or less and the organ function is good. Cisplatin plus etoposide is typically administered together with radiotherapy, since the risk of radiation pneumonia is known to be low when this combination is selected. The median survival time of LD-SCLC is 16 to 24 months and the 5-year survival rate is nearly 15{\%}. Conversely, the median survival time of ED-SCLC is 6-12 months, however, a long-term disease-free survival is rare. Chemotherapy alone is chosen for ED-SCLC. In the Japanese guideline, the combination of cisplatin plus irinotecan is the first choice if tolerable.",
author = "Yoichi Nakanishi",
year = "2016",
month = "2",
day = "20",
doi = "10.2482/haigan.56.43",
language = "English",
volume = "56",
pages = "43--47",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "1",

}

TY - JOUR

T1 - Chemotherapy for lung cancer (small-cell lung cancer)

AU - Nakanishi, Yoichi

PY - 2016/2/20

Y1 - 2016/2/20

N2 - Untreated small-cell lung cancer (SCLC) is highly sensitive to both chemotherapy and radiotherapy, although its growth is quite rapid. Clinically, SCLC is classified into limited disease (LD) and extensive disease (ED). Although there are no distinct criteria, LD is generally accepted to be a disease which is confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes without malignant effusion, i.e., a disease in which curative radiotherapy is applicable. Nearly 30% of SCLC is LD at the initial diagnosis. LD-SCLC is a potentially curable disease, and standard treatment is chemoradiotherapy, and the concurrent use of chemotherapy and radiotherapy is chosen particularly if the performance status of the patient is 2 or less and the organ function is good. Cisplatin plus etoposide is typically administered together with radiotherapy, since the risk of radiation pneumonia is known to be low when this combination is selected. The median survival time of LD-SCLC is 16 to 24 months and the 5-year survival rate is nearly 15%. Conversely, the median survival time of ED-SCLC is 6-12 months, however, a long-term disease-free survival is rare. Chemotherapy alone is chosen for ED-SCLC. In the Japanese guideline, the combination of cisplatin plus irinotecan is the first choice if tolerable.

AB - Untreated small-cell lung cancer (SCLC) is highly sensitive to both chemotherapy and radiotherapy, although its growth is quite rapid. Clinically, SCLC is classified into limited disease (LD) and extensive disease (ED). Although there are no distinct criteria, LD is generally accepted to be a disease which is confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes without malignant effusion, i.e., a disease in which curative radiotherapy is applicable. Nearly 30% of SCLC is LD at the initial diagnosis. LD-SCLC is a potentially curable disease, and standard treatment is chemoradiotherapy, and the concurrent use of chemotherapy and radiotherapy is chosen particularly if the performance status of the patient is 2 or less and the organ function is good. Cisplatin plus etoposide is typically administered together with radiotherapy, since the risk of radiation pneumonia is known to be low when this combination is selected. The median survival time of LD-SCLC is 16 to 24 months and the 5-year survival rate is nearly 15%. Conversely, the median survival time of ED-SCLC is 6-12 months, however, a long-term disease-free survival is rare. Chemotherapy alone is chosen for ED-SCLC. In the Japanese guideline, the combination of cisplatin plus irinotecan is the first choice if tolerable.

UR - http://www.scopus.com/inward/record.url?scp=84962580442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962580442&partnerID=8YFLogxK

U2 - 10.2482/haigan.56.43

DO - 10.2482/haigan.56.43

M3 - Article

AN - SCOPUS:84962580442

VL - 56

SP - 43

EP - 47

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 1

ER -